Zydus, one of the global pharmaceutical leaders, is set to launch VaxiFlu-4, India’s first quadrivalent influenza vaccine for the 2025 flu season. Designed as per WHO’s recommended composition, this inactivated vaccine offers protection against four flu strains, including A/Victoria/4897/2022 (H1N1), A/Croatia/10136RV/2023 (H3N2), B/Austria/1359417/2021 (B/Victoria), and B/Phuket/3073/2013 (B/Yamagata). By covering both influenza A and B strains, it provides broader protection and reduces the risk of vaccine mismatch.
Developed at Zydus’ Vaccine Technology Centre (VTC) in Ahmedabad, VaxiFlu-4 has been approved by the Central Drug Laboratory (CDL) and will be marketed under Zydus Vaxxicare, the company’s division dedicated to preventive healthcare. With its expertise in vaccine development, Zydus ensures that VaxiFlu-4 meets global safety and efficacy standards.
Influenza remains a major public health challenge, with seasonal outbreaks leading to 290,000-650,000 deaths globally every year, as per the World Health Organization (WHO). The virus spreads through airborne droplets from coughing and sneezing, as well as direct contact with infected surfaces. It can cause mild to severe illness, sometimes requiring hospitalization, especially among children, the elderly, and individuals with chronic conditions.
Annual flu vaccination is the most effective way to prevent influenza and its complications. With VaxiFlu-4, Zydus aims to strengthen India’s flu protection, ensuring better immunity and reduced disease burden in the upcoming flu season.
